Soligenix, Inc. Share Price

SNGX

US8342236044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/07/2025 am IST			5-day change	1st Jan Change
1.270 ^USD	+1.60%		+5.83%	-52.88%

02/07	Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma Solutions	CI
06/06	Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials	CI

Last Transcript: Soligenix, Inc.

Soligenix, Inc. - Special Call

19/24/19

More transcripts

Analysts' recommendations: Soligenix, Inc.

SOLIGENIX : Alliance Global Adjusts Price Target on Soligenix to $3.75 From $5.75, Reiterates Buy Rating	25/21/25	MT
SOLIGENIX : B. Riley Lowers Soligenix' PT to $1.50 from $2 on Unchanged Valuation Methodology, Keeps Neutral Rating	01/21/01	MT
SOLIGENIX : B. Riley Starts Soligenix at Buy With $4 Price Target	04/20/04	MT

More recommendations

Press Releases: Soligenix, Inc.

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones	08/07	PR
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions	01/07	PR
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials	06/06	AQ
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results	09/05	PR
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response	05/05	AQ

More press releases

Managers and Directors: Soligenix, Inc.

Manager	Title	Age	Since
Christopher Schaber CEO	Chief Executive Officer	58	01/08/2006
Jonathan Guarino DFI	Director of Finance/CFO	52	11/09/2019
Richard Straube CTO	Chief Tech/Sci/R&D Officer	73	06/01/2014

Director	Title	Age	Since
Christopher Schaber CHM	Chairman	58	08/10/2009
Gregg Lapointe BRD	Director/Board Member	66	01/03/2009
Robert Rubin BRD	Director/Board Member	79	01/10/2009

More insiders

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Employees

Sector

Biotechnology & Medical Research

Calendar

08/08 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
10/25/10	1.270 $	+1.60%	5,70,100
09/25/09	1.250 $	+2.46%	2,19,273
08/25/08	1.220 $	+8.93%	3,44,562
07/25/07	1.120 $	-6.67%	3,83,217
03/25/03	1.200 $	-4.76%	2,91,008

Delayed Quote Nasdaq, July 11, 2025 at 01:30 am IST

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

All our actual portfolios continue to outperform their benchmark.

Discover our performance

Capitalization	41.46L 35.47L 33.05L 30.57L 56.73L 36Cr 63.16L 3.95Cr 1.51Cr 17Cr 1.55Cr 1.52Cr 61Cr	P/E ratio 2025 *	-0.37x	P/E ratio 2026 *	-0.63x
Enterprise value	41.46L 35.47L 33.05L 30.57L 56.73L 36Cr 63.16L 3.95Cr 1.51Cr 17Cr 1.55Cr 1.52Cr 61Cr	EV / Sales 2025 *	-	EV / Sales 2026 *	4.15x
Free-Float	99.97%	Yield 2025 *	-	Yield 2026 *	-

Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma Solutions	02/07	CI
Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials	06/06	CI
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	10/05	CI
Soligenix Inc - Positive Outcome In 75% Of Ctcl Patients Treated With Hybryte For 18 Weeks	14/04	RE
Soligenix, Inc. Announces Interim Results from the Ongoing Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte	14/04	CI
Soligenix Announces Publication Demonstrating CiVax(TM) Booster Induces Rapid Broad Protection Against COVID-19 Variants	25/03	RE
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	22/03	CI
Soligenix, Inc. Auditor Raises 'Going Concern' Doubt	21/03	CI
Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte	14/01	CI
Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma	16/12	MT
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma	16/12	CI
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma	19/11	CI
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 for the Treatment of Behcet's Disease	14/11	CI

1 day	+1.60%
1 week	+5.83%
Current month	-3.05%
1 month	-32.09%
3 months	-32.80%
6 months	-60.31%
Current year	-52.88%

1 week	1.09	1.39
1 month	1.09	1.89
Current year	1.09	3.68
1 year	1.09	8.25
3 years	1.09	239.98
5 years	1.09	717.6
10 years	1.09	5,568

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SOLIGENIX, INC.	+1.60%	+5.83%	-83.57%	-99.11%	41.46L
ARGENX SE	-0.76%	+4.63%	+11.92%	+33.81%	3.47TCr
BIONTECH SE	+1.91%	+3.56%	+40.12%	-33.04%	2.81TCr
WUXI APPTEC CO., LTD.	+0.63%	-0.09%	+88.24%	-36.35%	2.8TCr
SUMMIT THERAPEUTICS INC.	+4.61%	+5.42%	+212.18%	+2,437.25%	1.92TCr
INSMED INCORPORATED	+0.20%	-1.17%	+32.23%	+289.76%	1.84TCr
GENMAB A/S	+0.48%	+8.82%	-20.34%	-43.69%	1.34TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.50%	+3.10%	+149.53%	-65.48%	1.33TCr
AKESO, INC.	+4.52%	+6.60%	+202.81%	+385.41%	1.24TCr
EXELIXIS, INC.	+2.50%	-2.12%	+104.85%	+105.22%	1.23TCr
Average	+1.43%	+2.50%	+73.80%	+297.38%	1.8TCr
Weighted average by Cap.	+1.02%	+3.85%	+78.98%	+311.45%

Soligenix, Inc. Share Price

Equities

SNGX

US8342236044

Biotechnology & Medical Research

Valuation: Soligenix, Inc.

Chart: Soligenix, Inc.

Latest news: Soligenix, Inc.

Last Transcript: Soligenix, Inc.

Analysts' recommendations: Soligenix, Inc.

Press Releases: Soligenix, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Soligenix, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

	2025 *	2026 *
Net sales	-	10L 9L 8L 7L 13.69L 8.57Cr 15.24L 95.33L 36.41L 4.01Cr 37.5L 36.73L 15Cr
Net income	-1.12Cr -95.83L -89.29L -82.58L -1.53Cr -96Cr -1.71Cr -11Cr -4.08Cr -45Cr -4.2Cr -4.11Cr -164.01Cr	-1.01Cr -86.42L -80.52L -74.47L -1.38Cr -87Cr -1.54Cr -9.63Cr -3.68Cr -40Cr -3.79Cr -3.71Cr -147.9Cr
Net Debt	-	-